Breast Adenocarcinoma — Trials

Breast Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 686
Recruiting: 381
Ph III recruiting: 45
Growth YoY: +8.5%
Industry share: 24%
Top sponsor: Fudan University
Termination share: 44.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (278)

clinicaltrialsPublishedShowing 151–200 of 212 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04762979	Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer	active not recruiting	Phase 2	44	Marina N SharifiOTHER	1	Jan 2, 2026	clinicaltrials
NCT03997123	Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290)	active not recruiting	Phase 3	923	AstraZenecaINDUSTRY	30